Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ATEC unstopable 9.33
That would be nice.
1O maybe tomorrow, if not more
ATEC another solid day 7.12 filled CT order.
closed at 7dollars a/h
ATEC solid day.solid week and still undervalued.
ATEC should be trading at $120M market cap at the very least or around $12 a share - and that is right now - this is so undervalued it is a joke! It may even be worth much, much more as they will be in the black in 2017. Chart now shows a gap to be filled at $16. I wouldn't be surprised if that gap gets filled soon. I also wouldn't be surprised to see this at $12 in a few weeks or maybe days. This will continue to melt up to a fair value.
ATEC up trend continues. All my L.T stocks after deep DD. Already mentioned my rules, solid balance sheet, plently on Cash, low Cap and risk/reward ratio.
the Company has recently obtained U.S. clearance for its new XYcor® Expandable Spinal Spacer System, which the Company plans to launch later this
ATEC cap under $30m vs 100m net assets after paying debt.it's 3 times current market cap.should be trading over $12 pps imo not sure if investors have realized it.
we estimate our total debt drawn will be approximately $45 (vs $125m,10Q), provides the company with credit facilities of up to $57.5 million
total assets=$136m! (10Q)
Alphatec Holdings Completes Sale of International Business to Globus Medical
Substantially reduced debt and improved balance sheet strengthens Alphatec’s financial position and enables future growth strategies
CARLSBAD, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a provider of spinal fusion technologies, today announced the completion of the previously announced sale of its international operations and distribution channel to Globus Medical (NYSE:GMED), a leading musculoskeletal implant manufacturer.
With the closing of the transaction, the Company is now focused solely on the U.S. market, which Alphatec believes constitutes nearly 65% of the world's spinal fusion market.
Over the past several years, the Company has focused its R&D programs and invested in the development of a leading, robust suite of products that are available to surgeons in the U.S. today—including Arsenal™ Degenerative, Arsenal Deformity and Battalion™ Universal Interbody. In addition, the Company has recently obtained U.S. clearance for its new XYcor® Expandable Spinal Spacer System, which the Company plans to launch later this year. The Company also made significant progress through its initiative to outsource its manufacturing operations—reducing capital investment in equipment, partnering with valued suppliers to provide flexible capacity, while achieving unit level cost reductions and margin improvements. As a result, Alphatec believes it is now better positioned to compete more effectively in the marketplace, accelerate growth and continue to improve profitability.
“Today marks the beginning of a new chapter for Alphatec,” said Jim Corbett, President and Chief Executive Officer of Alphatec Spine. “I am excited about the long-term prospects for the company as we pursue the U.S. spinal market with the resources we need to support continued investment in the commercialization of our robust product line. We have the right products, an exceptional team and a newly streamlined balance sheet to support our growth across the country, and we look forward to executing on our vision.”
Terms of the Transaction
Globus acquired Alphatec's international operations and distribution channel for a purchase price of $80 million in cash. Globus will also provide Alphatec a five-year senior secured credit facility of up to $30 million. In addition, Alphatec has entered into a supply agreement through which Alphatec will supply its products to Globus for up to five years.
New Capital Structure
With the closing of this transaction, Alphatec believes that it can now establish a new capital structure that appropriately reflects the capital needs of its U.S.-focused business and positions the company for achieving future profitability. As part of the closing, Alphatec implemented the following related to this new capital structure:
Drew down $25M of the $30M credit facility from Globus upon closing;
Paid off the existing Deerfield credit facility balance and retired the credit facility;
Reduced the MidCap Financial term loan to a $5M balance; and
Reduced the MidCap Financial revolver commitment to $22.5M.
With this, Alphatec expects to have paid down approximately $66 million of existing debt and debt-related expenses.
Concurrent with this transaction, Deerfield Management Company, L.P. has utilized its cashless exercise provision under its warrant agreements, converting its warrants to purchase up to 11.45 million shares of common stock to approximately 3.2 million shares on a pre-reverse split basis. This will constitute approximately 269 thousand shares on a post-reverse split basis. As a reminder, on August 25, 2016 the Company completed a one-for-twelve reverse stock split.
“As a result of this transaction, we are able to improve Alphatec’s forward-looking balance sheet by reducing our overall debt while providing the liquidity and reserves needed to invest in commercializing our robust product portfolio,” said Mike O’Neill, Alphatec’s Chief Financial Officer. “The new term loan from Globus, in conjunction with a planned revolving line of credit from MidCap Financial, provides the company with credit facilities of up to $57.5 million, which will offer sufficient liquidity and appropriate financing to successfully support Alphatec's transition to a U.S. market based company. Upon closing, we estimate our total debt drawn will be approximately $45 million. I would like to thank Deerfield who has been an excellent partner and we appreciate the support that they have provided to the company through the years. I am also pleased that MidCap will remain as a lender and provide funding for the company going forward. I want to thank them for their continued commitment and support to Alphatec.”
The Company expects that its stronger financial foundation coupled with its strong product portfolio will support future investments in its capital instrument base each year. These investments will be used to drive the commercial expansion of its new product lines, which are expected to contribute substantially to its planned growth profile. In addition, the Company has already made substantial headway towards its goal of reducing its operating expenses by $20 million. The Company expects this to continue for the remainder of 2016 and into 2017, translating to positive cash flow and profitability in the back half of 2017.
About Alphatec Spine
Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc., is a global medical device company that designs, develops, manufactures and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The Company's mission is to improve lives by delivering advancements in spinal fusion technologies. The Company and its affiliates market products in the U.S. and internationally via a direct sales force and independent distributors.
Additional information can be found at www.alphatecspine.com.
About Globus Medical
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.
Current cap $30m vs $80m purchase price (in Cash).just sayin.
Expect to see here upgrade rate+price."Globus acquired Alphatec's international operations and distribution channel for a purchase price of $80 million in cash. Globus will also provide Alphatec a five-year senior secured credit facility of up to $30 million. In addition, Alphatec has entered into a supply agreement through which Alphatec will supply its products to Globus for up to five years".
Expect to see here upgrade rate+price. Cap is only $35m!!
completed $80M sale. 9.4 Cash/share. Outstanding Shares 8,541,195 a/o Aug 25, 2016
https://www.owler.com/reports/alphatec-spine/alphatec-closes--80m-sale-of-international-operati/1472779320262?utm_source=twitter&utm_medium=social&utm_campaign=sectorNews_HealthCareServices
Can you confirm this tweet? ty."$ATEC sold part of their business for 80m in cash and a 30m credit facility. Also they received FDA clearance which is mentioned in this PR".
if i got it right, current cap( at 4.2 PPS) is about $35m. Outstanding Shares 8,541,195 a/o Aug 25, 2016
Five Million float... Should tun tommorow... Will watched close @ The opening
I say we open at $7 tomorrow...and then UP from there. We will be at around $20 a share in a few months.
I give this a $2 price target w 80 million coming n and intl operations no longer a burden.
Ahh! Saw the golden cross and freed up funds for Thursday then they go and drop news on us!
Just my luck
BOO-YA! $80M and $30M of credit!!! Holding 1.6M @ .32 Let the good times roll!
§
Hey Clay, I was wondering if you could share another chart on ATEC for us.
Picked back up some .32s but must say they went quick @ .40
Going to come back in next week @ .36 and see how this rolls. Something's up...hopefully Medtronic!
Good for $570K on the catalyst.
§
daily trend in tact but not the weekly. watch for .45 break but take profits in to the break
GLTA
TRENDTRADE2016
* * $ATEC Video Chart 06-22-16 * *
Link to Video - click here to watch the technical chart video
Well...don't know if it was a filing leak pop, but I'll take the six digit profits vs holding for a 1:8 to remain listed and get sold for 38¢ anyway.
Well worth that month of bid sitting!
Will settlement open the door to sale of Alphatech Spine? Medtronic is licking it's chops.
Loaded and ready for good things in ATEC!
§
Alphatec Holdings Incorporated (NASDAQ:ATEC) Shorted Shares Decreased By 5.6%
by Franklin Staff — May 23, 2016
The stock of Alphatec Holdings Incorporated (NASDAQ:ATEC) registered a decrease of 5.6% in short interest. ATEC’s total short interest was 2.36M shares in May as published by FINRA. Its down 5.6% from 2.51 million shares, reported previously. With 74,800 shares average volume, it will take short sellers 32 days to cover their ATEC’s short positions. The short interest to Alphatec Holdings Incorporated’s float is 3.64%. The stock is up 5.41% or $0.01 after the news, hitting $0.195 per share. About 317 shares traded hands. Alphatec Holdings Inc (NASDAQ:ATEC) has declined 45.71% since October 15, 2015 and is downtrending. It has underperformed by 47.12% the S&P500.
Alphatec Holdings, Inc. is a medical technology company. The company has a market cap of $19.92 million. The Firm through its subsidiary, Alphatec Spine, Inc. and its subsidiaries designs, develops, makes and markets products for the surgical treatment of spine disorders. It currently has negative earnings. The Company’s product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures.
Hope the selling is about done. Get a pop to maybe .27 tomorrow
Wish I knew. Very odd.
Yes it will run over a Dollar once they annunce the Q.
I tried to buy ATEC at market open yesterday. Robinhood broker failed to execute the trade and I missed a 44% gain because of that! Taking Tim Sykes advice--he said Robinhood is terrible at executing trades and recommended using brokers like ETrade and IB instead. It doesn't matter if there is zero commission charge at Robinhood if you can't make the trades sometimes!!!
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
181
|
Created
|
02/24/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |